{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:39:12Z","timestamp":1793090352571,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105546","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T14:59:26Z","timestamp":1786805966000},"page":"105546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["DNA damage response genes in lung cancer: Diagnostic, prognostic, and therapeutic implications \u2013 A narrative review"],"prefix":"10.1016","volume":"227","author":[{"given":"Ana-Karla","family":"Dur\u00e1n-Toribio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio F.","family":"Jim\u00e9nez-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Caball\u00e9-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Lucio-Lozada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Castillo-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Barrios-Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Romero-N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Hern\u00e1ndez-Pedro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1164-3779","authenticated-orcid":false,"given":"Oscar","family":"Arrieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105546_bib1","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1158\/1078-0432.CCR-23-0536","article-title":"Targeting replication stress and chemotherapy resistance with a combination of Sacituzumab Govitecan and Berzosertib: a phase I clinical trial","volume":"29","author":"Abel","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105546_bib2","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.36740\/WLek202109202","article-title":"Association between APE1 gene and lung cancer in Iraqi population","volume":"74","author":"Ahmed","year":"2021","journal-title":"Wiad. Lek."},{"key":"10.1016\/j.critrevonc.2026.105546_bib3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cllc.2021.02.009","article-title":"A dose-finding study followed by a phase II randomized, placebo-controlled trial of chemoradiotherapy with or without veliparib in stage III non-small cell lung cancer: SWOG 1206 (8811)","volume":"22","author":"Argiris","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105546_bib4","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3390\/pharmaceutics16091121","article-title":"ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer","volume":"16","author":"Barba","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2026.105546_bib5","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1158\/1535-7163.MCT-21-0305","article-title":"ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non-Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts","volume":"20","author":"Baschnagel","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105546_bib6","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41591-024-02808-y","article-title":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","volume":"30","author":"Besse","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105546_bib7","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cllc.2021.04.005","article-title":"A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer","volume":"22","author":"Byers","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105546_bib8","first-page":"45","article-title":"Genetic signatures of ERCC1 and ERCC2 expression, along with SNPs variants, unveil favorable prognosis in SCLC patients undergoing platinum-based chemotherapy","volume":"33","author":"Caliman","year":"2024","journal-title":"Oncol. Res."},{"key":"10.1016\/j.critrevonc.2026.105546_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/jclinpath-2018-205553","article-title":"TP53 and DNA-repair gene polymorphisms genotyping as a low-cost lung adenocarcinoma screening tool","volume":"72","author":"Cavic","year":"2019","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105546_bib10","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1038\/s41598-019-39594-4","article-title":"Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma","volume":"9","author":"Chae","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105546_bib11","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1038\/s41467-026-69262-x","article-title":"Targeting NHEJ activates STING signaling through MYC degradation to boost antitumor immunity in SCLC","volume":"17","author":"Chakraborty","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105546_bib12","article-title":"Association of ERCC family mutations with prognosis and immune checkpoint inhibitors response in multiple cancers","volume":"13","author":"Chen","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105546_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00262-024-03864-6","article-title":"Combination of ataxia telangiectasia and Rad3-related inhibition with ablative radiotherapy remodels the tumor microenvironment and enhances immunotherapy response in lung cancer","volume":"74","author":"Chen","year":"2024","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"10.1016\/j.critrevonc.2026.105546_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.708294","article-title":"DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer","volume":"11","author":"Dai","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105546_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1322187","article-title":"Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy","volume":"15","author":"Dennis","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105546_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","article-title":"DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications","volume":"24","author":"Drew","year":"2025","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.critrevonc.2026.105546_bib17","doi-asserted-by":"crossref","first-page":"6210","DOI":"10.1080\/21655979.2021.1964193","article-title":"Gene expression and prognosis of x-ray repair cross-complementing family members in non-small cell lung cancer","volume":"12","author":"Fan","year":"2021","journal-title":"Bioengineered"},{"key":"10.1016\/j.critrevonc.2026.105546_bib18","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3390\/diagnostics15081048","article-title":"The Prognostic and Predictive Roles of Ataxia-Telangiectasia Mutated (ATM) Expression in Patients with Metastatic Non-Small-Cell Lung Cancer Receiving Pembrolizumab Monotherapy Alone or in Combination with Chemotherapy","volume":"15","author":"Hamdard","year":"2025","journal-title":"Diagnostics"},{"key":"10.1016\/j.critrevonc.2026.105546_bib19","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1002\/cncr.25863","article-title":"DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma","volume":"117","author":"Han","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105546_bib20","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1515\/med-2022-0492","article-title":"Bioinformatics analysis reveals three key genes and four survival genes associated with youth-onset NSCLC","volume":"17","author":"Han","year":"2022","journal-title":"Open. Med."},{"key":"10.1016\/j.critrevonc.2026.105546_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3306189","article-title":"The Roles of EXO1 and RPA1 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy","volume":"2022","author":"He","year":"2022","journal-title":"Dis. Markers"},{"key":"10.1016\/j.critrevonc.2026.105546_bib22","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","article-title":"DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy","volume":"6","author":"Huang","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105546_bib23","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1038\/s41467-023-40578-2","article-title":"An ATR-PrimPol pathway confers tolerance to oncogenic KRAS-induced and heterochromatin-associated replication stress","volume":"14","author":"Igarashi","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105546_bib24","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the Evolution of Non\u2013Small-Cell Lung Cancer","volume":"376","author":"Jamal-Hanjani","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105546_bib25","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fonc.2020.00168","article-title":"Association of MSH2 Expression With Tumor Mutational Burden and the Immune Microenvironment in Lung Adenocarcinoma","volume":"10","author":"Jia","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105546_bib26","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.21037\/jtd-21-755","article-title":"The association between the ERCC1\/2 polymorphisms and radiotherapy efficacy in 87 patients with non-small cell lung cancer","volume":"13","author":"Jiang","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.critrevonc.2026.105546_bib27","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.21037\/jtd-2025-1113","article-title":"ATR expression as a prognostic biomarker in KRAS-mutated non-small cell lung cancer","volume":"17","author":"Jiang","year":"2025","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.critrevonc.2026.105546_bib28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1158\/1078-0432.CCR-22-2074","article-title":"A Phase I\/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer","volume":"29","author":"Jones","year":"2023","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105546_bib29","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jtho.2024.10.021","article-title":"Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929","volume":"20","author":"Karim","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105546_bib30","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.3390\/cancers14215305","article-title":"The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer","volume":"14","author":"Khaddour","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105546_bib31","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.21873\/anticanres.16399","article-title":"Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer","volume":"43","author":"Kim","year":"2023","journal-title":"Anticancer. Res."},{"key":"10.1016\/j.critrevonc.2026.105546_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241231260","article-title":"Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology","volume":"16","author":"Laguna","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105546_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.733533","article-title":"GDPLichi: a DNA Damage Repair-Related Gene Classifier for Predicting Lung Adenocarcinoma Immune Checkpoint Inhibitors Response","volume":"11","author":"Leng","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105546_bib34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000512641","article-title":"Contribution of XPD and XPF Polymorphisms to Susceptibility of Non-Small Cell Lung Cancer in High-Altitude Areas","volume":"24","author":"Li","year":"2021","journal-title":"Public. Health Genom."},{"key":"10.1016\/j.critrevonc.2026.105546_bib35","article-title":"Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient\/high microsatellite instability\/high tumor mutational burden: A case report and literature review","volume":"13","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105546_bib36","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1038\/s41598-025-88126-w","article-title":"EXO1 is a key gene for lung-resident memory T cells and has diagnostic and predictive values for lung adenocarcinoma","volume":"15","author":"Li","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105546_bib37","article-title":"Clinical value of MLH1-negative circulating tumor cells in lung cancer patients","volume":"98","author":"Liang","year":"2019","journal-title":"Med. (Baltim. )"},{"key":"10.1016\/j.critrevonc.2026.105546_bib38","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.7150\/ijbs.106925","article-title":"Cyclin Y interacts with Chk1 to activate RRM2\/STAT3 signaling and promotes radioresistance in non-small cell lung cancer","volume":"21","author":"Liu","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105546_bib39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41419-021-03804-7","article-title":"Small-molecule inhibition of APE1 induces apoptosis, pyroptosis, and necroptosis in non-small cell lung cancer","volume":"12","author":"Long","year":"2021","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105546_bib40","doi-asserted-by":"crossref","DOI":"10.21037\/tlcr-23-742","article-title":"Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review","volume":"13","author":"Mao","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105546_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/cancers18050820","article-title":"ATR Blockade Potentiates the Effects of Genotoxic Agents In Vitro and Promotes Antitumor Immunity in a Mouse Model of Non-Small Cell Lung Cancer","volume":"18","author":"Mavroeidi","year":"2026","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105546_bib42","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.3390\/cancers16193286","article-title":"Impact of Optimized Ku-DNA Binding Inhibitors on the Cellular and In Vivo DNA Damage Response","volume":"16","author":"Mendoza-Munoz","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105546_bib43","first-page":"1450","article-title":"Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer","volume":"31","author":"Mukherjee","year":"2022","journal-title":"Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105546_bib44","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.18.00264","article-title":"Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study","volume":"37","author":"Owonikoko","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105546_bib45","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/1759-7714.14865","article-title":"Characterization and mechanisms of radioresistant lung squamous cell carcinoma cell lines","volume":"14","author":"Pan","year":"2023","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105546_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000919","article-title":"Understanding EGFR heterogeneity in lung cancer","volume":"5","author":"Passaro","year":"2020","journal-title":"ESMO Open."},{"key":"10.1016\/j.critrevonc.2026.105546_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107831","article-title":"DNA double-strand break repair capacity and its pathway gene variants predict the risk and prognosis of lung cancer","volume":"192","author":"Peng","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105546_bib48","first-page":"4041","article-title":"Prognostic significance of Ape1\/ref-1 subcellular localization in non-small cell lung carcinomas","volume":"21","author":"Puglisi","year":"2001","journal-title":"Anticancer. Res."},{"key":"10.1016\/j.critrevonc.2026.105546_bib49","doi-asserted-by":"crossref","DOI":"10.21037\/jtd-23-1746","article-title":"Development and validation of a DNA damage repair-related gene-based prediction model for the prognosis of lung adenocarcinoma","volume":"15","author":"Qin","year":"2023","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.critrevonc.2026.105546_bib50","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/cncr.33885","article-title":"JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer","volume":"128","author":"Ramalingam","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105546_bib51","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000544892","article-title":"Heterogeneity of Lung Cancer: The Histopathological Diversity and Tumour Classification in the Artificial Intelligence Era","volume":"92","author":"Ramos","year":"2025","journal-title":"Pathobiology"},{"key":"10.1016\/j.critrevonc.2026.105546_bib52","article-title":"A three-subtype prognostic classification based on base excision repair and oxidative stress genes in lung adenocarcinoma and its relationship with tumor microenvironment","volume":"15","author":"Rao","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105546_bib53","article-title":"Targeting DNA Damage and Repair (DDR) Pathways: Advances in Understanding and Therapeutic Implications","volume":"9","author":"Rashid","year":"2024","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105546_bib54","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1158\/1078-0432.CCR-19-3529","article-title":"Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer","volume":"26","author":"Ricciuti","year":"2020","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105546_bib55","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1556-0864(25)00513-1","article-title":"Impact of DNA damage response score on immune markers in small cell lung cancer: Insights from NGS profiling and transcriptomic analysis","volume":"20","author":"Rosa","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105546_bib56","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2217\/bmm-2021-0565","article-title":"Polymorphisms in the MSH2 gene predict poor survival of North Indian lung cancer patients undergoing chemotherapy","volume":"16","author":"Singh","year":"2022","journal-title":"Biomark. Med."},{"key":"10.1016\/j.critrevonc.2026.105546_bib57","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.amjms.2022.07.005","article-title":"Structural, functional analysis and association of MSH6 rs1800932, rs1042821 polymorphisms with clinical outcome in North Indian lung cancer patients treated with platinum-based doublet chemotherapy","volume":"364","author":"Singh","year":"2022","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.critrevonc.2026.105546_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/bjbs.2024.11835","article-title":"Genetic Variants Associated With Response to Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer Patients: A Field Synopsis and Meta-Analysis","volume":"81","author":"Sito","year":"2024","journal-title":"Br. J. Biomed. Sci."},{"key":"10.1016\/j.critrevonc.2026.105546_bib59","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jtho.2023.10.001","article-title":"Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer","volume":"19","author":"Stockhammer","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105546_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/or.2022.8281","article-title":"Characterization of the nucleotide excision repair pathway and evaluation of compounds for overcoming the cisplatin resistance of non-small cell lung cancer cell lines","volume":"47","author":"Suzuki","year":"2022","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2026.105546_bib61","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2023.4025","article-title":"Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial","volume":"9","author":"Takahashi","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105546_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70861","article-title":"Circulating Tumour DNA in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer and Early Disease Progression After First-Line Osimertinib Treatment: The ELUCIDATOR Multicentre Prospective Observational Study","volume":"14","author":"Tamiya","year":"2025","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2026.105546_bib63","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317729270","article-title":"Genetic variants of SULT1A1 and XRCC1 genes and risk of lung cancer in Bangladeshi population","volume":"39","author":"Tasnim","year":"2017","journal-title":"Tumour Biol. J. Int. Soc. Oncodev. Biol. Med."},{"key":"10.1016\/j.critrevonc.2026.105546_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35882","article-title":"Artificial intelligence-driven microsatellite instability profiling reveals distinctive genetic features in patients with lung cancer","volume":"131","author":"Thomas","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105546_bib65","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ph15121475","article-title":"Targeting the DNA Damage Response Machinery for Lung Cancer Treatment","volume":"15","author":"Venugopala","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.critrevonc.2026.105546_bib66","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf373","article-title":"Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous nonsmall lung cancer (ETCTN 10313)","volume":"30","author":"Villaruz","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105546_bib67","article-title":"PARP-1 genetic polymorphism associated with radiation sensitivity of non-small cell lung cancer","volume":"28","author":"Wang","year":"2022","journal-title":"Pathol. Oncol. Res. POR"},{"key":"10.1016\/j.critrevonc.2026.105546_bib68","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.ijrobp.2024.01.202","article-title":"OTUB1 Targets CHK1 for Deubiquitination and Stabilization to Facilitate Lung Cancer Progression and Radioresistance","volume":"119","author":"Wang","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2026.105546_bib69","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1016\/j.apsb.2021.07.029","article-title":"DNA-PK inhibition by M3814 enhances chemosensitivity in non-small cell lung cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.critrevonc.2026.105546_bib70","article-title":"Pancancer Fine-Mapping of Mutational Intolerance Identifies CHEK1 as an Immunosuppressive Driver in Lung Adenocarcinoma","volume":"13","author":"Wang","year":"2026","journal-title":"Adv. Sci."},{"key":"10.1016\/j.critrevonc.2026.105546_bib71","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1186\/s12885-022-09954-x","article-title":"DNA damage repair gene signature model for predicting prognosis and chemotherapy outcomes in lung squamous cell carcinoma","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105546_bib72","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1186\/s12967-023-04634-1","article-title":"The enrichment of Fanconi anemia\/homologous recombination pathway aberrations in ATM\/ATR-mutated NSCLC was accompanied by unique molecular features and poor prognosis","volume":"21","author":"Wei","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105546_bib73","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.21037\/tcr-2024-2536","article-title":"The identification and prediction of lung adenocarcinoma prognosis using a novel gene signature associated with DNA replication","volume":"14","author":"Wu","year":"2025","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105546_bib74","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.21037\/tlcr-22-746","article-title":"DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced non-small cell lung cancer: a retrospective Chinese cohort study","volume":"11","author":"Xiao","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105546_bib75","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/1759-7714.14920","article-title":"Mutations and expressions of breast cancer 1\/2 in lung cancer","volume":"14","author":"Yan","year":"2023","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105546_bib76","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12931-026-03699-y","article-title":"Genomic characterization of DNA damage response pathway mutations reveals their adverse impact on EGFR-TKI efficacy in non-small cell lung cancer","volume":"27","author":"Yang","year":"2026","journal-title":"Respir. Res."},{"key":"10.1016\/j.critrevonc.2026.105546_bib77","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.10418","article-title":"A signature of tumor DNA repair genes associated with the prognosis of surgically-resected lung adenocarcinoma","volume":"8","author":"Yang","year":"2020","journal-title":"PeerJ"},{"key":"10.1016\/j.critrevonc.2026.105546_bib78","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12672-025-03775-7","article-title":"The value of DNA repair gene and TP53 co-mutation in predicting the response of non-small cell lung cancer to immunotherapy","volume":"17","author":"Ye","year":"2026","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105546_bib79","first-page":"6941","article-title":"Effect of ERCC2 rs13181 and rs1799793 polymorphisms and environmental factors on the prognosis of patients with lung cancer","volume":"12","author":"Zhang","year":"2020","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.critrevonc.2026.105546_bib80","article-title":"Bioinformatics-based drug repositioning and prediction of the main active ingredients and potential mechanisms of action for the efficacy of Dan-Lou tablet","volume":"14","author":"Zhang","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105546_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1680921","article-title":"The DDR-immune fitness score: a biomarker for guiding parp and immunotherapy synergy in extensive-stage small cell lung cancer","volume":"15","author":"Zhang","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105546_bib82","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/15384101.2022.2111769","article-title":"Chk1 inhibition-induced BRCAness synergizes with olaparib in p53-deficient cancer cells","volume":"22","author":"Zhao","year":"2023","journal-title":"Cell. Cycle"},{"key":"10.1016\/j.critrevonc.2026.105546_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101287","article-title":"Targeting DNA damage response pathways in tumor drug resistance: Mechanisms, clinical implications, and future directions","volume":"83","author":"Zhu","year":"2025","journal-title":"Drug. Resist. Updat."},{"key":"10.1016\/j.critrevonc.2026.105546_bib84","doi-asserted-by":"crossref","unstructured":"Chae Y. K., Anker J. F., Carneiro B. A., Chandra S., Kaplan J., Kalyan A., Santa-Maria C. A., Platanias L. C., Giles F. J. Genomic landscape of DNA repair genes in cancer. Oncotarget. 2016; 7: 23312-23321. Retrieved from https:\/\/www.oncotarget.com\/article\/8196\/.","DOI":"10.18632\/oncotarget.8196"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:07:39Z","timestamp":1793088459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":84,"alternative-id":["S1040842826004336"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105546","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA damage response genes in lung cancer: Diagnostic, prognostic, and therapeutic implications \u2013 A narrative review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105546","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105546"}}